The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFevertree Regulatory News (FEVR)

Share Price Information for Fevertree (FEVR)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,174.00
Bid: 800.00
Ask: 1,325.00
Change: 0.00 (0.00%)
Spread: 525.00 (65.625%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1,174.00
FEVR Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Update

24 Jan 2018 07:00

RNS Number : 7223C
Fevertree Drinks PLC
24 January 2018
 

24th January 2018

Fevertree Drinks plc

 ("Fever-Tree", the "Group" or the "Company")

 

Trading Update

Fever-Tree, the world's leading supplier of premium carbonated mixers, is pleased to announce its trading update for the year ended 31 December 2017.

The Company has delivered another period of very strong growth with full year revenue expected to be circa £169 million, reflecting growth of 66% on 2016 with sales in the second half expected to be ahead of the prior year period by 58%.

The performance in the UK in the second half of 2017 has once again been exceptionally strong. The Company gained significant market share from its competitors culminating in Fever-Tree ending the year as the number one mixer brand by value in the UK off-trade channel. (IRI - Total UK Retail Mixer Market value share - 13 weeks to 31/12/17).

Full year revenue in the UK is expected to be circa 96% ahead of 2016. The Group's performance over the Christmas period was particularly notable with impressive rate of sales growth across all channels, formats and flavours. The growth of the mixer category continues to accelerate, driven by Fever-Tree's unwavering focus on quality and supported by the on-going premiumisation of the wider spirits sector.

Sales in Continental Europe performed well in the second half of 2017, and it is anticipated that full year revenue will be circa 42% ahead of 2016.

In the USA, strong revenue growth also continued during the second half of 2017, and as a result, full year revenue for the territory is expected to be circa 39% ahead of 2016. The establishment of a North American office and the appointment of Charles Gibb as North American CEO, announced in December 2017, were significant milestones and reflect the Group's ambition and commitment to the North American market.

Rest of World sales growth accelerated in the second half of 2017 and full year revenue is expected to be circa 57% ahead of 2016.

In view of the Company's very strong sales performance in the final two months of the year, the Group took the opportunity to bring forward planned operational expenditure in the US to invest ahead of growth. Year-end net cash position is anticipated to be in line with Board expectations with significant cash balances still to collect given the strength of trading over the Christmas period.

FY17 expectations

Reflecting the continued strong performance through to the end of the year, the Board expects that the outcome for the full year will be comfortably ahead of market expectations.

Fever-Tree will announce its Preliminary Results on 13th March 2018.

Commenting on today's announcement, Tim Warrillow, Co-founder and CEO of Fever-Tree said:

"I am very proud of our performance in 2017 which has seen Fever-Tree end the year as the number one mixer brand at UK retail. Our pioneering approach and commitment to providing consumers with the highest quality range of mixers continues to capture peoples' imagination and is transforming the wider UK mixer category which as a result is now the fastest growing category across the soft drinks sector.

While we have seen strong growth across all regions, our performance in the UK over the Christmas period was once again exceptional. Our growing range of mixers and formats are appealing not only to our loyal customers but also bringing consumers back to the category and importantly attracting a new younger audience.

There is clear evidence that the same trends of premiumisation and mixability that we've previously highlighted are accelerating and we are increasingly excited by the global opportunity this presents particularly as we transition to our own operations in the US."

 

 

For further information:

 

Fevertree Drinks plc

Tim Warrillow, Co-founder and CEO

Andy Branchflower, Finance Director

Oliver Winters, Communications Director

+44 (0)20 7349 4922

FTI Consulting - Financial PR

Jonathon Brill

Georgina Goodhew

Fiona Walker

+44 (0)20 3727 1000

fever-tree@fticonsulting.com

Investec Bank plc - Nominated Adviser and Broker

Garry Levin

Alex Wright

David Anderson

+44 (0)20 7597 5970

 

 

Notes to Editors:

 

Fever-Tree is the world's leading supplier of premium carbonated mixers for alcoholic spirits by retail sales value, with distribution to over 60 countries worldwide. Based in the UK, the brand was launched in 2005 to provide high quality mixers which could cater to the growing demand for premium spirits, in particular gin, but also increasingly for vodka, rum and whisky. The Company now sells a range of carbonated mixers to hotels, restaurants, bars and cafes ("On Trade") as well as selected retail outlets ("Off Trade").

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTLLFFALIIVFIT
Date   Source Headline
9th May 20247:00 amRNSNotice of AGM
7th May 20247:00 amRNSGrant of Options
1st May 20247:00 amRNSTotal Voting Rights
27th Mar 20247:00 amRNSHolding(s) in Company
26th Mar 20247:00 amRNSFY23 Preliminary Results to 31 December 2023
25th Jan 202412:05 pmRNSDirector/PDMR Shareholding
25th Jan 20247:00 amRNSFY23 pre-close trading update
18th Jan 20242:30 pmRNSAdmission Application
18th Jan 20242:30 pmRNSBlock Admission Application
14th Dec 20232:33 pmRNSDirectorate Change
1st Dec 20237:00 amRNSBlock Listing Return
1st Dec 20237:00 amRNSTotal Voting Rights
1st Nov 20238:55 amRNSTotal Voting Rights
26th Oct 20233:25 pmRNSDirector/PDMR Shareholding
28th Sep 20236:20 pmRNSHolding(s) in Company
14th Sep 202312:18 pmRNSDirector/PDMR Shareholding
12th Sep 20236:25 pmRNSFever-Tree FY23 Interim Results - Replacement
12th Sep 20237:00 amRNSFever-Tree FY23 Interim Results
1st Aug 20232:16 pmRNSTotal Voting Rights
3rd Jul 20234:00 pmRNSTotal Voting Rights
1st Jun 20237:00 amRNSBlock Listing Return
1st Jun 20237:00 amRNSTotal Voting Rights
25th May 20231:54 pmRNSResult of AGM
25th May 20237:00 amRNSBoard Changes
25th May 20237:00 amRNSAGM Trading Statement
12th May 202311:25 amRNSHolding(s) in Company
5th May 20237:00 amRNSGrant of Options
2nd May 20237:00 amRNSTotal Voting Rights
21st Apr 20231:08 pmRNSNotice of AGM
22nd Mar 20237:00 amRNSFY22 Preliminary Results to 31 December 2022
8th Mar 20239:49 amRNSHolding(s) in Company
8th Feb 20232:56 pmRNSStandard form for notification of major holdings
30th Jan 20234:32 pmRNSHolding(s) in Company
26th Jan 20237:00 amRNSFY22 pre-close trading update
17th Jan 20239:45 amRNSStandard form for notification of major holdings
19th Dec 20227:00 amRNSBlock Admission Application
12th Dec 20227:00 amRNSDomenic De Lorenzo to succeed Bill Ronald as Chair
1st Dec 20229:00 amRNSBlock Listing Return
21st Nov 20227:00 amRNSChange Of Nominated Advisor and Corporate Broker
15th Nov 20226:18 pmRNSStandard form for notification of major holdings
1st Nov 20227:00 amRNSTotal Voting Rights
17th Oct 20223:09 pmRNSStandard form for notification of major holdings
4th Oct 202210:25 amRNSDirector/PDMR Shareholding
3rd Oct 20229:00 amRNSDirector/PDMR Shareholding
13th Sep 20227:00 amRNSFever-Tree FY22 Interim Results
1st Sep 20227:00 amRNSTotal Voting Rights
24th Aug 202212:06 pmRNSStandard form for notification of major holdings
19th Jul 20229:57 amRNSDirector/PDMR Shareholding
18th Jul 20227:00 amRNSDirector/PDMR Shareholding
15th Jul 20224:00 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.